摘要
目的:研究米非司酮与亮丙瑞林联用对子宫肌瘤的效果。方法:选择2021年1月—2023年12月就诊于我院的80例子宫肌瘤患者作为研究对象,采用抽签法随机分为对照组和观察组,每组40例。对照组单用米非司酮,观察组加用亮丙瑞林。比较两组临床疗效、症状评分、性激素水平、血清因子[胰岛素样生长因子-l(IGF-1)、基质金属蛋白酶-9(MMP-9)、肿瘤坏死因子-α(TNF-α)、血管内皮生长因子(VEGF)、超敏C-反应蛋白(hs-CRP)]。结果:治疗后,观察组有效率高于对照组(P<0.05);观察组倦怠乏力、乳房胀痛、月经过多、小腹胀痛和经期延长症状评分低于对照组(P<0.05);观察组血清LH、E2、FSH和P水平(P<0.05);观察组IGF-1、MMP-9、TNF-α、VEGF和hs-CRP水平低于对照组(P<0.05)。结论:米非司酮与亮丙瑞林联用能提高子宫肌瘤的疗效,减轻其症状,改善性激素水平,其机制可能与下调血清IGF-1、MMP-9、TNF-α、VEGF和hs-CRP水平有关。
Objective:To study the effect of the combination of mifepristone and leuprorelin on uterine fibroids.Methods:Eighty patients with uterine fibroids who visited our hospital from January 2021 to December 2023 were selected as the research subjects.They were randomly divided into a control group and an observation group using a lottery method,with 40 patients in each group.The control group received mifepristone alone,while the observation group received leuprorelin in addition.Compare the clinical efficacy,symptom scores,sex hormone levels,and serum factors[insulin-like growth factor-l(IGF-1),matrix metalloproteinase-9(MMP-9),tumor necrosis factor-α(TNF-α),vascular endothelial growth factor(VEGF),high-sensitivity C-reactive protein(hs CRP)]between two groups.Results:After treatment,the effective rate of the observation group was higher than that of the control group(P<0.05).The scores of lassitude,breast distending pain,menorrhagia,abdominal distending pain and prolonged menstrual period in the observation group were lower than those in the control group(P<0.05).The levels of serum LH,E2,FSH and P in the observation group(P<0.05).The levels of IGF-1,MMP-9,TNF-α,VEGF and hs-CRP in the observation group were lower than those in the control group(P<0.05).Conclusion:Mifepristone combined with leuprorelin can improve the efficacy of uterine fibroids,reduce their symptoms and improve sex hormone levels.The mechanism may be related to the down-regulation of serum IGF-1,MMP-9,TNF-α,VEGF and hs-CRP levels.
作者
曹妍妍
王亚茹
侯俊芳
CAO Yanyan;WANG Yaru;HOU Junfang(Department of Gynecology,Kaifeng People's Hospital,Kaifeng 475000,Henan,China;Department of Obstetrics and Gynecology,Huaihe Hospital of Henan University,Kaifeng 475000,Henan,China)
出处
《中国药物滥用防治杂志》
CAS
2024年第11期2079-2081,共3页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
米非司酮
亮丙瑞林
子宫肌瘤
Mifepristone
Liangbingruilin
Uterine fibroids